The International Journal of Neuropsychopharmacology
September 1, 2026
Christopher Sheridan, Guillaume Thuery, K Brennan et al.
Abstract Background Serotonergic psychedelics have recently re-emerged as promising therapeutic agents in psychiatry, showing positive outcomes in clinical trials for treatment-resistant depression, major depression, and PTSD. However, their effects on the immune system are poorly characterized. It remains unclear whether these compounds exert immunomodulatory effects that contribute to their...
The International Journal of Neuropsychopharmacology
September 1, 2026
Ella Nield, Martha López-canul, Antonio Inserra et al.
Abstract Background Pain conditions are major health problems resulting in physical, psychological and social impairment (1), and health care costs (2,3). Within the last decade, research has demonstrated that 5-HT2A agonists including psilocybin and LSD elicit spiritual experiences (4) and functional connectivity changes between diverse brain areas (5). Therefore, it is pertinent to...
Translational Psychiatry
September 1, 2026
Sandra M. Martin-Guerrero, Marco Taddei-Tardón, Jessica L Maltman et al.
Abstract Psychedelic drugs can induce intense changes in perception and thought, and some also promote long-lasting adaptations in brain circuits that are being explored for treatment of mood and anxiety disorders. How these compounds differ at the level of intracellular signaling, and how hallucinogenic drugs diverge from related non-hallucinogenic forms, is poorly understood. A central...
Clinical Neuropsychopharmacology and Addiction
September 1, 2026
Beatrice Dal Bianco, Matteo Buonarroti, Alessandro Lo Jacono et al.
Background: Epidemiological data on psychedelic use in Italy is limited. In this study, Italian responders in the Global Psychedelic Survey 2025 were subanalyzed to describe patterns of use, motivations, subjective experiences, and health correlates. Methods: Adults (≥21 years) with lifetime psychedelic exposure, residing in or born in Italy or San Marino, were surveyed in a web-based,...
Neuropsychopharmacology Reports
September 1, 2026
Daisuke Ibi, Rika Takaba, Keisuke Yoshida et al.
Psychedelics such as psilocybin and lysergic acid diethylamide (LSD) exert hallucinogenic effects through stimulation of serotonin 5-HT2A receptors (5-HT2ARs) in the cerebral cortex. In recent years, numerous reports have demonstrated that psychedelics are effective in treating various psychiatric disorders such as major depressive disorder (MDD), treatment-resistant depression (TRD), and...
Nursing Edição Brasileira
August 27, 2026
Ana Júlia Costa Matias Gomes, Jéssica Camilo Ramos Rodrigues, Valber Pinheiro Padilha Filho
Os psicodélicos clássicos, como a psilocibina, o LSD e a DMT, têm despertado crescente interesse na psiquiatria moderna devido ao seu potencial terapêutico em transtornos resistentes ao tratamento. O mecanismo de ação primário dessas substâncias envolve o agonismo dos receptores de serotonina 5-HT2A, localizados principalmente no córtex pré-frontal. Esta revisão sistemática analisou como a...
Pharmacological Research
August 26, 2026
Mattia Giovenzana, Noemi Nicosia, Stefano Spinosa et al.
Neurodevelopmental disorders (NDDs) comprise a heterogeneous group of conditions arising from altered brain development and leading to impairments in social, cognitive, emotional, and motor domains. Clinical manifestations are highly variable in severity and symptom profile, reflecting the complex and multifactorial etiology of NDDs. Available treatments are limited to early behavioral...
Current Addiction Reports
August 18, 2026
Michael J. Broman, Jhuma N. Acharya, Kaltum Ahmed et al.
Abstract Purpose of Review We highlight key findings and methodological issues from recent research on the abuse liability of classic psychedelics, utilizing a GRADE to assess the quality of the evidence. Recent Findings Studies using various designs suggest that classic psychedelics (e.g., psilocybin, LSD) have low abuse potential and less dependence liability than other drugs. However, public...
British Journal of Clinical Pharmacology
August 7, 2026
J. Nadler, Michaela J. Sommer, Annette Zschiesche et al.
Numerous analogues of the psychedelic and internationally controlled hallucinogen LSD have been described; however, only a limited number have been systematically investigated. This report presents the first case with an analytically confirmed ingestion of ETH-LAD (6-ethyl-6-nor-lysergic acid diethylamide), the N-ethyl derivative of LSD. An adolescent patient developed moderate to severe...
Molecular Psychiatry
August 4, 2026
Kim P. C. Kuypers, Natasha L. Mason, Aurelie Carlier et al.
Women experience a disproportionate burden of affective and stress-related disorders, with symptom variability shaped by endocrine transitions across the menstrual cycle, pregnancy, postpartum, and menopause. Although psychedelic-assisted therapies are increasingly investigated for these conditions, hormonal state represents a largely unaccounted determinant of variability in exposure,...